Behavior of MV140 vaccine to prevent recurrent urinary tract infections in patients with metabolic syndrome and smoking
DOI:
https://doi.org/10.48193/revistamexicanadeurologa.v82i6.959Keywords:
Recurrent urinary tract infections, inmunoprophylaxis, MV140 vaccine, metabolic syndrome, smokingAbstract
Introduction: This study analyzed patients with metabolic syndrome and smokers treated with MV140 vaccine to prevent recurrent UTI.
Material and methods: 342 patients with recurrent UTI received MV140 vaccine between 2017 and 2020 in Barcelona, Spain. Variables analyzed: number of UTI at 3 and 6 months after MV140, age, gender, diabetes mellitus, body mass index, hypertension, total cholesterol, HDL-cholesterol, triglycerides and smoking. Patients were divided in Group 1: metabolic syndrome (2 or more variables), Group 2: no metabolic syndrome (less than 2 variables). On the other hand, patients were classified into smokers and non-smokers.
Results: Mean age was 74, 82% were women. At the beginning, 88,9% had 3-5 UTI. Overall effectiveness with MV140 was 72.5% at 3 months and 56.2% at 6 months.
Group 1 (36%) presented 0-1 UTI in 78.9% and 62.6% at 3 and 6 months. In Group 2 (64%) the results were 69% and 52.5%. Comparing both groups, no statistically significant differences were observed (p=0,25, p=0,26). Smokers had 77.4% and 61.3% at 3 and 6 months, and non-smokers had 69.3% and 52.7%. There were also no statistically significant differences (p = 0.5, p = 0.36).
Group 1 and smoking (28,7%) had 82% at 3 months and 66.3% at 6 months. Group 2 and no smoking (71,3%) reached 60.3% and 52% at 3 and 6 months. There were no statistically significant differences between both groups.
Conclusions: The overall efficacy of MV140 was high and safe, without side effects.
Patients with metabolic syndrome and smokers may benefit from this treatment.
References
Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7(12):653–60. doi: https://doi.org/10.1038/nrurol.2010.190
Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgraduate Medicine. 2017;129(2):242–58. doi: https://doi.org/10.1080/00325481.2017.1246055
Chipa-Paucar Y. Comorbilidades asociadas a infección de tracto urinario por Escherichia Coli Blee positivo del Hospital Vitarte. 2017 - 2018: Comorbidities associated with urinary tract infection by positive escherichia coli blee, in internal medicine service, Ate Vitarte Hospital. 2017 - 2018. Revista de la Facultad de Medicina Humana. 2019;19(3):1–1. doi: https://doi.org/10.25176/RFMH.v19i3.2162
Barutell Rubio L. Paciente diabética con infecciones urinarias de repetición. Diabetes Práctica. 2016;7(4):169–224
Nitzan O, Elias M, Chazan B, Saliba W. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. DMSO. 2015;8:129–36. doi: https://doi.org/10.2147/DMSO.S51792
Geerlings SE. Urinary tract infections in patients with diabetes mellitus: epidemiology, pathogenesis and treatment. International Journal of Antimicrobial Agents. 2008;31(Supplement 1):54–7. doi: https://doi.org/10.1016/j.ijantimicag.2007.07.042
Toledo J, Cubillo G, Gómez O. Asociación entre obesidad e infecciones: un estudio de corte transversal. Revista Med. 2014;22(1):28–34. doi: https://doi.org/10.18359/rmed.1017
Sinha MD, Postlethwaite RJ. Urinary tract infections and the long-term risk of hypertension. Current Paediatrics. 2003;7(13):508–12. doi: https://doi.org/10.1016/j.cupe.2003.08.010
Lorenzo-Gómez MF, Santos-Antunes MT, Nieto-Huertos A, Lorenzo-Gómez A, Marquez-Sanchez MT, Flores-Fraile MC, et al. The influence of smoking on bacterial resistance after vaccine or antibiotic prophylaxis against recurrent urinary tract infections. Actas Urol Esp (Engl Ed). 2020;44(7):497–504. doi: https://doi.org/10.1016/j.acuro.2020.04.002
Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12. doi: https://doi.org/10.1007/s11906-018-0812-z
Pfau A, Sacks TG. Effective Prophylaxis for Recurrent Urinary Tract Infections during Pregnancy. Clinical Infectious Diseases. 1992;14(4):810–4. doi: https://doi.org/10.1093/clinids/14.4.810
Bauer HW, Rahlfs VW, Lauener PA, Blessmann GSS. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents. 2002;19(6):451–6. doi: https://doi.org/10.1016/S0924-8579(02)00106-1
Naber KG, Cho Y-H, Matsumoto T, Schaeffer AJ. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents. 2009;33(2):111–9. doi: https://doi.org/10.1016/j.ijantimicag.2008.08.011
Bauer HW, Alloussi S, Egger G, Blümlein H-M, Cozma G, Schulman CC. A Long-Term, Multicenter, Double-Blind Study of an Escherichia Coli Extract (OM-89) in Female Patients with Recurrent Urinary Tract Infections. European Urology. 2005;47(4):542–8. doi: https://doi.org/10.1016/j.eururo.2004.12.009
Prieto L, Esteban M, Salinas J, Adot JM, Arlandis S, Peri L, et al. Documento de consenso de la Asociación Española de Urología en el manejo de las infecciones del tracto urinario recurrentes no complicadas. Actas Urológicas Españolas. 2015;39(6):339–48. doi: https://doi.org/10.1016/j.acuro.2014.10.003
Prattley S, Geraghty R, Moore M, Somani BK. Role of Vaccines for Recurrent Urinary Tract Infections: A Systematic Review. European Urology Focus. 2020;6(3):593–604. doi: https://doi.org/10.1016/j.euf.2019.11.002
Tamadonfar KO, Omattage NS, Spaulding CN, Hultgren SJ. Reaching the End of the Line: Urinary Tract Infections. Microbiology Spectrum. 2019;7(3):7.3.17. doi: https://doi.org/10.1128/microbiolspec.BAI-0014-2019
González Pedraza Avilés A, Dávila Mendoza R, Acevedo Giles O, Ramírez Martínez ME, Gilbaja Velázquez S, Valencia Gómez C, et al. Infección de las vías urinarias: prevalencia, sensibilidad antimicrobiana y factores de riesgo asociados en pacientes con diabetes mellitus tipo 2. Revista Cubana de Endocrinología. 2014;25(2):57–65.
Nseir W, Farah R, Mahamid M, Sayed-Ahmad H, Mograbi J, Taha M, et al. Obesity and recurrent urinary tract infections in premenopausal women: a retrospective study. Int J Infect Dis. 2015;41:32–5. doi: https://doi.org/10.1016/j.ijid.2015.10.014
La Vecchia C, Negri E, D’Avanzo B, Savoldelli R, Franceschi S. Genital and urinary tract diseases and bladder cancer. Cancer Res. 1991;51(2):629–31.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Revista Mexicana de Urología
This work is licensed under a Creative Commons Attribution 4.0 International License.
